Extended Data Table 1 Summary of the sensitivity analysis for progression-free survival (intention-to-treat set)

From: Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

  1. Median progression-free survival and 95% CIs were estimated by the Kaplan–Meier method. HRs and corresponding 95% two-sided CIs were estimated by a stratified Cox proportional hazards model. Treatment group difference was compared using the two-sided stratified log-rank test, and no adjustments were made for multiplicity. P value used for descriptive purposes only.
Back to article page